Acetylation was previously thought to occur exclusively on histones, but recent high-throughput screens have identified thousands of non-histone substrates. Despite the identification of these sites, little is known about how these acetyltransferase enzymes target their substrates. Gcn5 is the catalytic acetyltransferase found within the highly conserved SAGA complex. Recently, a member of this complex, Ada2, was found to impact Gcn5 substrate selection. In the yeast model organism Saccharomyces cerevisiae, a synthetic substrate developed from a proposed Gcn5-specific consensus sequence is used to identify regulators of Gcn5 substrate selection. This work is the first to demonstrate that addition of a consensus sequence is enough to confer acetylation of a non-substrate. With this method, Ada3 was identified as a key regulator, and acetylome profiling identified novel targets for Gcn5 dependent acetylation specifically regulated by Ada3. This system could be adapted for other acetyltransferases to identify regulators of substrate selection.

Escherichia coli 5'-nucleotidase is a periplasmically localised enzyme capable of hydrolysing a broad range of substrates, including all 5'-ribo- and 5'-deoxyribonucleotides, uridine diphosphate sugars, and a number of synthetic substrates such as bis (r-nitrophenyl) phosphate. The enzyme has been shown to contain at least one zinc ion following purification, and to have two metal binding sites in the catalytic cleft. 5'-Nucleotidase activity is significantly stimulated by the addition of particular divalent metal ions, most notably cobalt which results in a 30-50 fold increase in activity. Significant sequence homology between the E. coli 5'-nucleotidase and members of the Ser/Thr protein phosphatase family in the catalytic site has lead to 5'-nucleotidase being included in this protein family. This thesis describes the development of a rapid purification methodology for milligram quantities of 5'-nucleotidase, and the investigation of a number of physical and biochemical properties of the enzyme with the aim of comparing these properties to those of certain catalytic site mutants. The molecular weight of the mature protein was estimated as 58219 daltons, with a specific activity for 5'-AMP, in the presence of 4 mM Co2+ and 13 mM Ca2+ at pH 6.0, of 730 mmol/min/mg. The presence of up to two zinc ions associated with the purified enzyme was observed using ICP-ES analysis, suggesting both metal ion binding sites are occupied by zinc in vivo, and some degree of displacement of zinc by cobalt could be observed. Mass spectrometry data, gathered at 60 and 70 mS orifice potential, suggested the presence of a small proportion of material with a mass 118 to 130 daltons greater than the main 5'-nucleotidase mass estimation. This study suggests that this mass difference, only evident at the lower orificepotential, is due to the presence of two zinc ions closely associated with 5'-nucleotidase. To account for the observed high level of activation of 5'-nucleotidase activity by particular divalent metal ions, this thesis describes a proposed model in which these divalent ions may displace the zinc ion at one of the metal ion binding sites. This displacement only occurs at one of the two metal ion binding sites, with the other metal binding site retaining the zinc ion already present. Studies with purified enzyme, each with a single amino acid substitution, lend support to this hypothesis and suggest the identity of the metal ion binding site at which displacement occurs. Seven key catalytic site residues (Asp-41, His-43, Asp-84, His-117, Glu-118, His-217 and His-252) were selected on the basis of sequence conservation within the Ser/Thr protein phosphatases and 5'-nucleotidases. X-ray crystallographic data published by others during this study implicated five of the selected residues (Asp-41, His-43, Asp-84, His-217 and His-252) directly in metal ion binding, including two residues from each metal ion binding site and one directly involved in both sites (Asp-84). The remaining two residues (His-117 and Glu-118) are highly conserved but were not thought to play direct roles in metal ion binding. The seven selected residues were modified by site-directed mutagenesis, and the effect of the amino acid substitutions upon the kinetic properties of 5'-nucleotidase activity was determined. Residues hypothesised to be involved in metal ion displacement, and subsequent activation of 5'-nucleotidase activity, were identified by reductions in metal ion affinity and increased levels of activation by cobalt compared to the wild type 5'-nucleotidase. This study suggests that the metal binding site, M2, that includes residues Asp-84, His-217 and His-252, is involved in metal ion displacement, while the other metal binding site, M1, is not. This, in turn, suggests the metal binding sites are functionally non-equivalent and kinetically distinct. No residues were identified in this study as playing significant roles in substrate binding, as there was no significant reduction observed in affinity for 5'-AMP observed in any of the catalytic site mutants.

Diss. (sammanfattning) Stockholm : Karol. inst., 2004. / Härtill 5 uppsatser.

Thesis (Ph.D.). / Written for the Dept. of Medicine, Division of Experimental Medicine. Title from title page of PDF (viewed 2008/05/09). Includes bibliographical references.

Equine infectious anemia virus (EIAV) has been used as a model to investigate protective mechanisms against lentiviruses. Unlike other lentiviruses, EIAV replication can be eventually controlled in most infected horses leading to an inapparent carrier state free of overt clinical signs which can last for many years. Maintenance of this carrier state is absolutely dependent on active immune responses as evidenced by the fact that immunosuppressive drugs can induce the recurrence of disease. However, the immune mechanisms that are responsible for this control of infection are not yet identified. As the resolution of the initial infection is correlated with the appearance of the virus-specific cytotoxic T lymphocytes (CTL), it appears that cellular immune responses play an important role. However, most studies into this protective mechanism have been limited to the identification of specific epitopes, usually at a single time point in the infection. Few studies have examined the cellular immune responses to the viral antigens throughout the infection period. Since the virus undergoes rapid mutation following infection, the adaptive immune response must also evolve to meet this challenge. Previously, the EIAV envelope (gp90) protein was shown to be the primary determinant of vaccine efficacy. Here, we hypothesized that the maturation of cellular immune responses is a lengthy process and involves envelope-specific T cell recognition shifting from immunodominant variable determinants to conserved immunorecessive determinants during the initial stages of the EIAV infection. The first part of this dissertation was to develop a new in vivo method to identify envelope-specific T cell responses. The second part of this dissertation was to investigate whether envelope-specific T cell recognition evolved in EIAV-infected ponies. Finally, the mechanisms for this T cell immunodominant shifting were also investigated from the point of both virus sequence mutation and T cell clone expansion and contraction. Also, a new EIAV attenuated vaccine which contained a consensus gp90 sequence was tested to see if it facilitated T cell recognition of the more conserved regions early in the infection. Our results indicated that envelope-specific T cell recognition patterns changed over time. Early after infection, dominant immune responses to the peptides in the carboxyl-terminus variable region were identified. By six months post infection, the recognized peptides spanned the entire envelope sequence, with a shift to the amino-terminus conserved region. The mechanisms responsible for this change remain unclear, but analysis of T cell receptor repertoire indicated that T cell clonal expansion and contraction might be one of the reasons. Our demonstration that envelope-specific peptide recognition shifts from the variable to the more conserved regions provides evidence that the maturation of cell mediated immune response is parallelled with long-term control of this infection.

The first goal of this work focused on the development of an amine dehydrogenase (AmDH) from a leucine dehydrogenase using site-directed mutagenesis. We aimed at reductively aminating a prochiral ketone to a chiral amine by using leucine dehydrogenase (LeuDH) as a starting template. This initial work was divided into two stages. The first focused mutagenesis to a specific residue (K68) that we know is key to developing the target functionality. Subsequently, mutagenesis focused on residues known to be in close proximity to a key region of the substrate (M65 and K68). This approach allowed for reduced library size while at the same time increased chances of generating alternate substrate specificity. An NAD+-dependent high throughput assay was optimized and will be discussed. The best variants showed specific activity in mU/mg range towards deaminating the target substrate. The second goal of this work was the development of a thermostable glucose dehydrogenase (GDH) starting with the wild-type gene from Bacillus subtilis. GDH is able to carry out the regeneration of both NADH and NADPH cofactors using glucose as a substrate. We applied the structure-guided consensus method to identify 24 mutations that were introduced using overlap extension. 11 of the tested variants had increased thermal stability, and when combined a GDH variant with a half-life ~3.5 days at 65℃ was generated--a ~10⁶increase in stability when compared to the wild-type. The final goal of this work was the characterization of GDH in homogeneous organic-aqueous solvent systems and salt solutions. Engineered GDH variants showed increased stability in all salts and organic solvents tested. Thermal stability had a positive correlation with organic solvent and salt stability. This allowed the demonstration that consensus-based methods can be used towards engineering enzyme stability in uncommon media. This is of significant value since protein deactivation in salts and organic solvents is not well understood, making a priori design of protein stability in these environments difficult.

Thesis (Ph.D. in Pharmacology) -- University of Colorado Denver, 2007. / Typescript. Includes bibliographical references (leaves 203-212; 260-261). Free to UCD affiliates. Online version available via ProQuest Digital Dissertations;

Asparagine (N)-linked glycosylation occurs on 90% of membrane and secretory proteins and drives folding and trafficking along the secretory pathway. The N-glycan can be attached to an N-X-T/S-Y (X,Y ≠ P) consensus site by one of two oligosaccharyltransferase (OST) STT3 enzymatic isoforms either during protein translation (co-translational) or after protein translation has completed (post-translational). While co-translational N-glycosylation is both rapid and efficient, post-translational N-glycosylation occurs on a much slower time scale and, due to competition with protein degradation and forward trafficking, could be detrimental to the success of a peptide heavily reliant on post-translational N-glycosylation. In evidence, mutations in K+ channel subunits that shift N-glycosylation kinetics have been directly linked to cardiac arrhythmias. My thesis work focuses on identifying primary sequence factors that affect the rate of N-glycosylation. To identify the molecular determinants that dictate whether a consensus site acquires its initial N-glycan during or after protein synthesis, I used short (~ 100-170 aa) type I transmembrane peptides from the KCNE family (E1-E5) of K+ channel regulatory subunits. The lifetime of these small membrane proteins in the ER translocon is short, which places a significant time constraint on the co-translational N-glycosylation machinery and increases the resolution between co- and post-translational events. Using rapid metabolic pulse-chase experiments described in Chapter II, I identified several molecular determinants among native consensus sites in the KCNE family that favor co-translational N-glycosylation: threonine containing-consensus sites (NXT), multiple N-terminal consensus sites, and long C-termini. The kinetics could also be shifted towards post-translational N-glycosylation by converting to a serine containing-consensus site (NXS), reducing the number of consensus sites in the peptide, and shortening the C-termini. In Chapter III, I utilized an E2 scaffold peptide to examine the N-glycosylation kinetics of the middle X residue in an NXS consensus site. I found that large hydrophobic and negatively charged residues hinder co-translational N-glycosylation, while polar, small hydrophobic, and positively charged residues had the highest N-glycosylation efficiencies. Poorly N-glycosylated NXS consensus sites with large hydrophobic and negatively charged X residues had a significantly improved co-translational N-glycosylation efficiency upon conversion to NXT sites. Also in Chapter III, I adapted a siRNA knockdown strategy to definitively identify the OST STT3 isoforms that perform co- and post-translational N-glycosylation for type I transmembrane substrates. I found that the STT3A isoform predominantly performs co-translational N-glycosylation while the STT3B isoform predominantly performs post-translational N-glycosylation, in agreement with the roles of these enzymatic subunits on topologically different substrates. Taken together, these findings further the ability to predict the success of a consensus site by primary sequence alone and will be helpful for the identification and characterization of N-glycosylation deficiency diseases.

A busca por uma construção vacinal contra o HIV-1 é urgente. Os linfócitos T CD4+ têm assumido um papel de destaque no campo de vacinas por participar no controle da replicação do HIV-1, seja auxiliando as funções efetoras de linfócitos T CD8+ e a produção de anticorpos por linfócitos B ou mesmo agindo de forma citotóxica sobre macrófagos infectados. A utilização de sequências consenso do grupo M do HIV-1 é apontada como uma das maneiras de se contornar os problemas relacionados à diversidade viral. Além disso, é preciso construir vacinas que apresentem potencial de induzir respostas imunes com grande cobertura populacional. Com o intuito de induzir respostas amplas de linfócitos T CD4+ contra diversos subtipos do HIV-1 em uma população geneticamente diversa para moléculas HLA-DR, identificamos em nosso trabalho prévio 34 peptídeos promíscuos (previstos de se ligarem a múltiplas moléculas HLA-DR) e conservados da sequência consenso do grupo M do HIV-1. Desenvolvemos uma vacina de DNA codificando 7 peptídeos de Env (HIVenv7) e outra vacina (HIVBr27) codificando os demais 27 peptídeos. A vacina HIVBr27 foi imunogênica em camundongos BALB/c, induzindo uma resposta ampla e polifuncional de linfócitos T CD4+ e CD8+. A vacina HIVenv7 foi pouco imunogênica e mostrou-se capaz de suprimir a resposta induzida pela HIVBr27 em regime de co-imunização. No presente trabalho demonstramos que a imunização com HIVBr27 induz uma resposta imune celular mediada por linfócitos T CD4+ e CD8+ contra peptídeos de diferentes subtipos do HIV-1. Além disso, a imunização com HIVBr27 mostrou-se parcialmente protetora contra a infecção pelo vírus Vaccinia recombinante codificando as proteínas Gag e Pol do HIV-1. Ensaios in vitro demonstraram que os peptídeos codificados pela HIVBr27 se ligam a múltiplas moléculas HLA de classe II e são reconhecidos por células de pacientes infectados pelo HIV-1. Demonstramos também que a vacina HIVenv7 não possui propriedades imunossupressoras consistentes, contrariando os resultados obtidos previamente. Os peptídeos codificados pela HIVenv7 se ligaram a múltiplas moléculas HLA de classe II, mas apresentaram baixa frequência de reconhecimento por células de pacientes infectados pelo HIV-1. Acreditamos que a vacina HIVBr27 possui potencial de induzir uma resposta imune de grande cobertura populacional e direcionada a diferentes variantes do HIV-1. Por outro lado, a vacina HIVenv7 se mostrou pouco imunogênica e não deve ser utilizada em estudos futuros / The search for an HIV-1 vaccine construct is urgent. The CD4+ T cells have assumed a prominent role in the vaccine field participating in the control of HIV-1 replication either by helping CD8+ T cell effector function and B cell-mediated antibody production or by acting as citotoxic cells on infected macrophages. The use of HIV-1 M-group consensus sequences is pointed as an alternative to overcome viral diversity. Besides, it is necessary to construct vaccines that would potentially induce immune responses with broad population coverage. Intending to induce a broad CD4+ T-cell immune response against different HIV-1 subtypes in a population bearing diverse HLA-DR molecules we have previously identified 34 promiscuous peptides (potentially binding to multiple HLA-DR molecules) and conserved within the HIV-1 M-group consensus sequence. We construct a DNA vaccine encoding 7 Env peptides (HIVenv7) and another vaccine (HIVBr27) encoding 27 peptides. The HIVBr27 vaccine was immunogenic in BALB/c mice, inducing a broad and polyfunctional CD4+ and CD8+ T-cell response. The HIVenv7 vaccine was much less immunogenic and suppressed HIVBr27-induced immune responses when co-immunized. Here, we have shown that HIVBr27 immunization leads to a cross-clade CD4+ and CD8+ T-cell immune response. Besides, HIVBr27 immunization has partially protected mice challenged with a recombinant Vaccinia virus encoding HIV-1 Gag e Pol. In vitro assays have shown that HIVBr27- encoded peptides bind to multiple HLA class II molecules and are recognized by HIV- 1-infected patients. We have also shown that HIVenv7 has no consistent immunosuppressive properties, contradicting our previous results. The HIVenv7- encoded peptides bound to multiple HLA class II molecules but were recognized by a low number of HIV-1-infected patients. We believe that our vaccine HIVBr27 has potential to induce an immune response with broad population coverage, towards different HIV-1 variants. On the other hand, the HIVenv7 vaccine was poorly immunogenic and should not be used in future studies

A busca por uma construção vacinal contra o HIV-1 é urgente. Os linfócitos T CD4+ têm assumido um papel de destaque no campo de vacinas por participar no controle da replicação do HIV-1, seja auxiliando as funções efetoras de linfócitos T CD8+ e a produção de anticorpos por linfócitos B ou mesmo agindo de forma citotóxica sobre macrófagos infectados. A utilização de sequências consenso do grupo M do HIV-1 é apontada como uma das maneiras de se contornar os problemas relacionados à diversidade viral. Além disso, é preciso construir vacinas que apresentem potencial de induzir respostas imunes com grande cobertura populacional. Com o intuito de induzir respostas amplas de linfócitos T CD4+ contra diversos subtipos do HIV-1 em uma população geneticamente diversa para moléculas HLA-DR, identificamos em nosso trabalho prévio 34 peptídeos promíscuos (previstos de se ligarem a múltiplas moléculas HLA-DR) e conservados da sequência consenso do grupo M do HIV-1. Desenvolvemos uma vacina de DNA codificando 7 peptídeos de Env (HIVenv7) e outra vacina (HIVBr27) codificando os demais 27 peptídeos. A vacina HIVBr27 foi imunogênica em camundongos BALB/c, induzindo uma resposta ampla e polifuncional de linfócitos T CD4+ e CD8+. A vacina HIVenv7 foi pouco imunogênica e mostrou-se capaz de suprimir a resposta induzida pela HIVBr27 em regime de co-imunização. No presente trabalho demonstramos que a imunização com HIVBr27 induz uma resposta imune celular mediada por linfócitos T CD4+ e CD8+ contra peptídeos de diferentes subtipos do HIV-1. Além disso, a imunização com HIVBr27 mostrou-se parcialmente protetora contra a infecção pelo vírus Vaccinia recombinante codificando as proteínas Gag e Pol do HIV-1. Ensaios in vitro demonstraram que os peptídeos codificados pela HIVBr27 se ligam a múltiplas moléculas HLA de classe II e são reconhecidos por células de pacientes infectados pelo HIV-1. Demonstramos também que a vacina HIVenv7 não possui propriedades imunossupressoras consistentes, contrariando os resultados obtidos previamente. Os peptídeos codificados pela HIVenv7 se ligaram a múltiplas moléculas HLA de classe II, mas apresentaram baixa frequência de reconhecimento por células de pacientes infectados pelo HIV-1. Acreditamos que a vacina HIVBr27 possui potencial de induzir uma resposta imune de grande cobertura populacional e direcionada a diferentes variantes do HIV-1. Por outro lado, a vacina HIVenv7 se mostrou pouco imunogênica e não deve ser utilizada em estudos futuros / The search for an HIV-1 vaccine construct is urgent. The CD4+ T cells have assumed a prominent role in the vaccine field participating in the control of HIV-1 replication either by helping CD8+ T cell effector function and B cell-mediated antibody production or by acting as citotoxic cells on infected macrophages. The use of HIV-1 M-group consensus sequences is pointed as an alternative to overcome viral diversity. Besides, it is necessary to construct vaccines that would potentially induce immune responses with broad population coverage. Intending to induce a broad CD4+ T-cell immune response against different HIV-1 subtypes in a population bearing diverse HLA-DR molecules we have previously identified 34 promiscuous peptides (potentially binding to multiple HLA-DR molecules) and conserved within the HIV-1 M-group consensus sequence. We construct a DNA vaccine encoding 7 Env peptides (HIVenv7) and another vaccine (HIVBr27) encoding 27 peptides. The HIVBr27 vaccine was immunogenic in BALB/c mice, inducing a broad and polyfunctional CD4+ and CD8+ T-cell response. The HIVenv7 vaccine was much less immunogenic and suppressed HIVBr27-induced immune responses when co-immunized. Here, we have shown that HIVBr27 immunization leads to a cross-clade CD4+ and CD8+ T-cell immune response. Besides, HIVBr27 immunization has partially protected mice challenged with a recombinant Vaccinia virus encoding HIV-1 Gag e Pol. In vitro assays have shown that HIVBr27- encoded peptides bind to multiple HLA class II molecules and are recognized by HIV- 1-infected patients. We have also shown that HIVenv7 has no consistent immunosuppressive properties, contradicting our previous results. The HIVenv7- encoded peptides bound to multiple HLA class II molecules but were recognized by a low number of HIV-1-infected patients. We believe that our vaccine HIVBr27 has potential to induce an immune response with broad population coverage, towards different HIV-1 variants. On the other hand, the HIVenv7 vaccine was poorly immunogenic and should not be used in future studies